Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.87 |
| ▸ | PGR | P06401 | 3/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | AR | P10275 | 2/20 | 0.87 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | APEX1 | P27695 | 1/20 | 0.87 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.87 |
| ▸ | IKBKB | O14920 | 1/20 | 0.87 |
| ▸ | CHUK | O15111 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.87 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.87 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL1943653 | 1.00 | HIF1A (0.87) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL120210 | 0.98 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL28873762 | 0.98 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4888419 | 0.96 | NR3C1 (0.86) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL124724 | 0.96 | NR3C1 (0.86) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7272 | 0.96 | NR3C1 (0.86) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL25306130 | 0.96 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1530977 | 0.96 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL27837446 | 0.95 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20485506 | 0.94 | NR3C1 (0.83) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-118302171-A | Lymphocyte populations and methods for producing the same | AVM生物技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| JP-2023108567-A | Method for producing steroid 17α,21-diesters | 同仁医薬化工株式会社 | 2023-08-04 | — | — | JP | disclosed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230172950-A1 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | AVM BIOTECHNOLOGY, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-116096421-A | Methods for treating remission-type multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230096897-A1 | Lymphocyte Population and Methods for Producing Same | AVM BIOTECHNOLOGY, LLC (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023034377-A1 | LYMPHOCYTE POPULATION AND METHODS FOR PRODUCING SAME | AVM BIOTECHNOLOGY, LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-4142736-A1 | GLUCOCORTICOID RECEPTOR (GR) MODULATORS FOR TREATING A SARS-COV-2 VIRUS | AVM Biotechnology, LLC (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115666583-A | Glucocorticoid Receptor (GR) modulators for the treatment of SARS-COV-2 virus | AVM生物技术有限责任公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4110902-A1 | LYPMPHOCYTE POPULATION AND METHODS FOR PRODUCING SAME | AVM Biotechnology, LLC (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115516085-A | Lymphocyte populations and methods for producing same | AVM生物技术有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021222385-A1 | GLUCOCORTICOID RECEPTOR (GR) MODULATORS FOR TREATING A SARS-COV-2 VIRUS | AVM BIOTECHNOLOGY, LLC (US) | 2021-11-04 | — | — | WO | disclosed |
| US-7250546-B2 | Adhesive preparations | HISAMITSU PHARMACEUTICALS CO., INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20070083139-A1 | Adhesive preparations | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1238664-B1 | ADHESIVE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-20030109819-A1 | Adhesive preparations | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1238664-A1 | ADHESIVE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-09-11 | — | — | EP | disclosed |